Ticker

Jupiter Neurosciences, Inc. (NASDAQ: JUNS - Get Free Report) was the recipient of a significant growth in short interest during the month of March. As of March 31st, there was short interest totaling 126,917 shares, a growth of 59.6% from the March 15th total of 79,512 shares. Currently, 0.7% of the shares of the stock are

Jupiter, Florida--(Newsfile Corp. - April 13, 2026) - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, will present at the Centri Capital Conference on Tuesday, April 14 at Nasdaq in New York City. Christer Rosén, Chairman and CEO will discuss the Company's recent performance and future growth plans.

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Jupiter Neurosciences, Inc. (NASDAQ: JUNS) resulting from allegations that Jupiter Neurosciences may have issued materially misleading business information to the investing public. So what: If you purchased Jupiter Neurosciences securities you may…

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Jupiter Neurosciences, Inc. (NASDAQ: JUNS) resulting from allegations that Jupiter Neurosciences may have issued materially misleading business information to the investing public. So what: If you purchased Jupiter Neurosciences securities you may…